[{"id":"2da9c54d-f433-496f-be98-f97e66600d34","acronym":"MCC-20575","url":"https://clinicaltrials.gov/study/NCT04610671","created_at":"2021-01-19T20:32:23.268Z","updated_at":"2025-02-25T16:38:06.492Z","phase":"Phase 1","brief_title":"Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC","source_id_and_acronym":"NCT04610671 - MCC-20575","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • cretostimogene grenadenorepvec (CG0070)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 01/18/2025","primary_completion_date":" 01/18/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-06"},{"id":"26c9faf7-877b-4f34-b6b7-c5dc32f7be60","acronym":"BOND2","url":"https://clinicaltrials.gov/study/NCT02365818","created_at":"2021-01-18T11:15:58.531Z","updated_at":"2024-07-02T16:36:31.942Z","phase":"Phase 2","brief_title":"Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure","source_id_and_acronym":"NCT02365818 - BOND2","lead_sponsor":"CG Oncology, Inc.","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cretostimogene grenadenorepvec (CG0070)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 06/02/2015","start_date":" 06/02/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2021-04-14"}]